Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2017

01-04-2017 | Research Article

Polypharmacotherapy and blood products as risk factors for venous thromboembolism in postsurgical patients: a case–control study

Authors: Alenka Premuš Marušič, Daniel Petrovič, Aleš Mrhar, Igor Locatelli

Published in: International Journal of Clinical Pharmacy | Issue 2/2017

Login to get access

Abstract

Background After surgical procedures, patients are at high risk of developing venous thromboembolism, clinically manifested as deep vein thrombosis (DVT) or pulmonary embolism (PE). Objective To evaluate the influence of polypharmacotherapy, comorbidity, drug treatments, packed red blood cells application, adequacy of thromboprophylaxis, and patient characteristics on the occurrence of DVT or PE in postsurgical patients. Setting The surgical department at Murska Sobota General Hospital, Slovenia. Methods In this retrospective case control study, the records of 286 surgical patients were analysed: DVT or PE group (n = 144) and control group (n = 142). The number of prescribed drugs and drug–drug interactions were reviewed, together with prescription of low-molecular-weight heparins. The odds ratios (OR) of risk factors for DVT or PE were calculated using a multivariable logistic regression model. Main outcome measure Risk factors assessment for the occurrence of DVT or PE in surgical patients. Results Polypharmacotherapy (OR 2.02, 95% CI 1.03–3.96, p = 0.040) and packed red blood cells application (OR 3.44, 95% CI 1.46–8.10, p = 0.005) were associated with an increased risk of PE or DVT after surgery. Inadequate thromboprophylaxis with low-molecular-weight heparins significantly increased the likelihood of DVT or PE (OR 2.50, 95% CI 1.41–4.43, p = 0.002). There were no differences between the groups concerning the treatment with nonsteroidal anti-inflammatory drugs, benzodiazepines or antipsychotics. Conclusions Patients with polypharmacotherapy and patients receiving red blood cells should be monitored more closely after surgery as they are more likely to develop DVT or PE.
Literature
1.
go back to reference Dickson BC. Venous thrombosis: on the history of Virchow’s triad. Univ Toronto Med J. 2004;81:166–71. Dickson BC. Venous thrombosis: on the history of Virchow’s triad. Univ Toronto Med J. 2004;81:166–71.
2.
3.
4.
go back to reference Chung I, Lip GY. Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb. 2003;33:449.CrossRefPubMed Chung I, Lip GY. Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb. 2003;33:449.CrossRefPubMed
5.
go back to reference Blann AD. How a damaged blood vessel wall contributes to thrombosis and hypertension. Pathophysiol Haemost Thromb. 2003;33:445.CrossRefPubMed Blann AD. How a damaged blood vessel wall contributes to thrombosis and hypertension. Pathophysiol Haemost Thromb. 2003;33:445.CrossRefPubMed
7.
go back to reference Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients : antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians evidence-based clinical practical guidelines. 9th ed. Chest. 2012;141:e227S.CrossRefPubMedPubMedCentral Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients : antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians evidence-based clinical practical guidelines. 9th ed. Chest. 2012;141:e227S.CrossRefPubMedPubMedCentral
8.
go back to reference Kistner RL, Ball JJ, Nordyke RA, Freeman GC. Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities. Am J Surg. 1972;124:169.CrossRefPubMed Kistner RL, Ball JJ, Nordyke RA, Freeman GC. Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities. Am J Surg. 1972;124:169.CrossRefPubMed
9.
go back to reference White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8.PubMed White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8.PubMed
10.
go back to reference Hawkins D. The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. Pharmacotherapy. 2004;24:179S–83S.CrossRefPubMed Hawkins D. The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. Pharmacotherapy. 2004;24:179S–83S.CrossRefPubMed
11.
go back to reference Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet. 1986;2(8499):143–6.CrossRefPubMed Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet. 1986;2(8499):143–6.CrossRefPubMed
13.
go back to reference Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. Prevention of venous thromboembolism. Chest. 2008;133:381S–453S.CrossRefPubMed Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. Prevention of venous thromboembolism. Chest. 2008;133:381S–453S.CrossRefPubMed
14.
go back to reference Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1_suppl):64S–94S.CrossRefPubMed Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1_suppl):64S–94S.CrossRefPubMed
15.
go back to reference DiMarco J, Domanski MJ, Knatterud GL, Scheinman M, Singer D, Waldo A, Wolf PA, Wyse DG. Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol. 1993;22:1830–40.CrossRef DiMarco J, Domanski MJ, Knatterud GL, Scheinman M, Singer D, Waldo A, Wolf PA, Wyse DG. Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol. 1993;22:1830–40.CrossRef
16.
17.
go back to reference Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med. 1994;120:449.CrossRefPubMed Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med. 1994;120:449.CrossRefPubMed
18.
go back to reference Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11:116.CrossRefPubMed Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11:116.CrossRefPubMed
19.
go back to reference Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352–60.CrossRefPubMed Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352–60.CrossRefPubMed
20.
go back to reference Ramsay MA. Acute postoperative pain management. Proc (Bayl Univ Med Cent). 2000;13(3):244–7. Ramsay MA. Acute postoperative pain management. Proc (Bayl Univ Med Cent). 2000;13(3):244–7.
21.
go back to reference Conti V, Venegoni M, Cocci A, Fortino I, Lora A, Barbui C. Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study. BMC Psychiatry. 2015;29(15):92.CrossRef Conti V, Venegoni M, Cocci A, Fortino I, Lora A, Barbui C. Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study. BMC Psychiatry. 2015;29(15):92.CrossRef
22.
go back to reference Flegel KM, Cole CH. Inappropriate antidiuresis during carbamazepine treatment. Ann Intern Med. 1977;87:722.CrossRefPubMed Flegel KM, Cole CH. Inappropriate antidiuresis during carbamazepine treatment. Ann Intern Med. 1977;87:722.CrossRefPubMed
23.
24.
go back to reference Scherz N, Labarere J, Mean M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2010;182(9):1178–83.CrossRefPubMedPubMedCentral Scherz N, Labarere J, Mean M, Ibrahim SA, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2010;182(9):1178–83.CrossRefPubMedPubMedCentral
25.
go back to reference Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629.CrossRefPubMed Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629.CrossRefPubMed
26.
go back to reference Lu WH, Wen YW, Chen LK, Hsiao FY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187:E130.CrossRefPubMedPubMedCentral Lu WH, Wen YW, Chen LK, Hsiao FY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187:E130.CrossRefPubMedPubMedCentral
27.
go back to reference Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.CrossRefPubMed Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.CrossRefPubMed
28.
go back to reference Ismail M, Igbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35(3):455–62.CrossRefPubMed Ismail M, Igbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35(3):455–62.CrossRefPubMed
29.
go back to reference Delafuente J. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–43.CrossRefPubMed Delafuente J. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–43.CrossRefPubMed
31.
go back to reference Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62:2261.CrossRefPubMedPubMedCentral Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62:2261.CrossRefPubMedPubMedCentral
34.
go back to reference Schartum-Hansen H, Løland KH, Svingen GF, Seifert R, Pendersen ER, Nordrehaug JE, et al. Use of loop diuretics is associated with increased mortality in patients with suspected coronary artery disease, but without systolic heart failure or renal impairment: an observational study using propensity score matching. PLoS ONE. 2015;10(6):e0124611.CrossRefPubMedPubMedCentral Schartum-Hansen H, Løland KH, Svingen GF, Seifert R, Pendersen ER, Nordrehaug JE, et al. Use of loop diuretics is associated with increased mortality in patients with suspected coronary artery disease, but without systolic heart failure or renal impairment: an observational study using propensity score matching. PLoS ONE. 2015;10(6):e0124611.CrossRefPubMedPubMedCentral
35.
go back to reference Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to ‘Mexican aspirin’ (dipyrone). South Med J. 1996;89:612.CrossRefPubMed Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to ‘Mexican aspirin’ (dipyrone). South Med J. 1996;89:612.CrossRefPubMed
36.
go back to reference van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RM, Wilson JH, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159:369.CrossRefPubMed van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RM, Wilson JH, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159:369.CrossRefPubMed
37.
38.
go back to reference Premuš Marušič A, Kovačič S, Mrhar A, Petrovič D. Thromboprophylaxis in surgical patients with pulmonary embolism and deep vein thrombosis in Murska Sobota General Hospital. Zdrav Vestn (Slovenian Medical Journal). 2014;83(supl: I):21–9. Premuš Marušič A, Kovačič S, Mrhar A, Petrovič D. Thromboprophylaxis in surgical patients with pulmonary embolism and deep vein thrombosis in Murska Sobota General Hospital. Zdrav Vestn (Slovenian Medical Journal). 2014;83(supl: I):21–9.
39.
go back to reference Vervacke A, Lorent S, Motte S. Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium. Int J Clin Pharm. 2014;36(5):1007–13.CrossRefPubMed Vervacke A, Lorent S, Motte S. Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium. Int J Clin Pharm. 2014;36(5):1007–13.CrossRefPubMed
Metadata
Title
Polypharmacotherapy and blood products as risk factors for venous thromboembolism in postsurgical patients: a case–control study
Authors
Alenka Premuš Marušič
Daniel Petrovič
Aleš Mrhar
Igor Locatelli
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2017
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0441-7

Other articles of this Issue 2/2017

International Journal of Clinical Pharmacy 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.